Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. Hosting Providers
  13. CDN Services

We began analyzing https://link.springer.com/article/10.1007/BF02087671, but it redirected us to https://link.springer.com/article/10.1007/BF02087671. The analysis below is for the second page.

Title[redir]:
Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-α | Digestive Diseases and Sciences
Description:
To test the role of immune reactivity in the pathogenesis of hepatitis C, serum soluble immune factors were measured in a cohort of 57 patients with chronic hepatitis C, and in 20 healthy subjects. Levels of interleukin-1β, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and interleukin-6 were detected in some, but not all, HCV patients and were in general undetectable in healthy subjects. Patients had significantly higher concentrations of neopterin (P=0.0026), β2-microglobulin (P=0.046), soluble interleukin-2 receptor (P=0.021), and soluble CD8 (P<0.039), than healthy controls; conversely, interferon-γ levels were significantly lower (P=0.023). Significant correlations were observed between β2-microglobulin concentration and Knodell

Matching Content Categories {📚}

  • Health & Fitness
  • Education
  • Science

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 80,486,609 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don’t know how the website earns money.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Doi.org might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

hepatitis, google, scholar, chronic, soluble, hepatology, article, patients, levels, liver, interleukin, immune, access, serum, quiroga, carreño, viral, disease, interferon, privacy, cookies, content, research, pathogenesis, significantly, βmicroglobulin, treatment, nonb, immunol, information, publish, search, factors, therapeutic, response, interferonα, subjects, factor, outcome, therapy, peripheral, blood, cells, open, virus, nona, clin, recombinant, data, log,

Topics {✒️}

granulocyte-macrophage colony-stimulating factor granulocyte colony-stimulating factor tumor necrosis factor-α month download article/chapter vitro cell-mediated cytotoxicity activated cell-mediated immunity recombinant interferon-alpha 2a article digestive diseases soluble immune factors privacy choices/manage cookies peripheral blood monocytes soluble interleukin-2 receptor full article pdf recombinant alpha interferon recombinant alpha-interferon fundación jiménez díaz soluble interleukin-2 receptors interferon-α liver autologous liver cells interferon-gamma production chronic liver diseases altered immune reactivity adaptive immune responses significantly higher concentrations interferon-α treatment serum ifn-gamma european economic area metabolic disorders published immunoelectron microscopic observations intraportal lymphoid nodule randomized controlled trial escalating dose regime 5′-oligoadenylate synthetase activity chronic viral disease interferon-alpha treatment chronic active hepatitis liver biopsy specimens conditions privacy policy chronic viral hepatitis related subjects numerical scoring system van thiel dh julio martin bsc β2-microglobulin expression long-term clinical chronic liver disease accepting optional cookies chronic posttransfusion hepatitis interferon-γ levels sustained biochemical response

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-α
         description:To test the role of immune reactivity in the pathogenesis of hepatitis C, serum soluble immune factors were measured in a cohort of 57 patients with chronic hepatitis C, and in 20 healthy subjects. Levels of interleukin-1β, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and interleukin-6 were detected in some, but not all, HCV patients and were in general undetectable in healthy subjects. Patients had significantly higher concentrations of neopterin (P=0.0026), β2-microglobulin (P=0.046), soluble interleukin-2 receptor (P=0.021), and soluble CD8 (P<0.039), than healthy controls; conversely, interferon-γ levels were significantly lower (P=0.023). Significant correlations were observed between β2-microglobulin concentration and Knodell's index (r=0.638,P=0.00045), the score of piecemeal necrosis (r=0.572,P=0.0023), and the degree of fibrosis (r=0.527,P=0.0056). Interleukin-2 levels correlated significantly with Knodell's index (r=0.412,P=0.037), and the degree of lobular cytolysis (r=0.389,P=0.048). According to therapeutic outcome, pretreatment levels of soluble CD8 were only significantly elevated (P=0.042) in patients with a sustained biochemical response. On interferon-α treatment, the levels of β2-microglobulin, neopterin, and soluble interleukin-2 receptor increased significantly (P<0.05), irrespective of therapy outcome. In summary, HCV patients have an altered immune reactivity that might play a role in the pathogenesis of chronic hepatitis C, and might influence the therapeutic outcome to interferon-γ.
         datePublished:
         dateModified:
         pageStart:2485
         pageEnd:2496
         sameAs:https://doi.org/10.1007/BF02087671
         keywords:
            chronic hepatitis C
            pathogenesis
            soluble immune factors
            interferon-α therapy
            Gastroenterology
            Hepatology
            Oncology
            Transplant Surgery
            Biochemistry
            general
         image:
         isPartOf:
            name:Digestive Diseases and Sciences
            issn:
               1573-2568
               0163-2116
            volumeNumber:39
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers-Plenum Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Juan Antonio Quiroga
               affiliation:
                     name:Hepatology Unit, Fundación Jiménez Díaz
                     address:
                        name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Julio Martin
               affiliation:
                     name:Hepatology Unit, Fundación Jiménez Díaz
                     address:
                        name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Margarita Pardo
               affiliation:
                     name:Hepatology Unit, Fundación Jiménez Díaz
                     address:
                        name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Vicente Carreño
               affiliation:
                     name:Hepatology Unit, Fundación Jiménez Díaz
                     address:
                        name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-α
      description:To test the role of immune reactivity in the pathogenesis of hepatitis C, serum soluble immune factors were measured in a cohort of 57 patients with chronic hepatitis C, and in 20 healthy subjects. Levels of interleukin-1β, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and interleukin-6 were detected in some, but not all, HCV patients and were in general undetectable in healthy subjects. Patients had significantly higher concentrations of neopterin (P=0.0026), β2-microglobulin (P=0.046), soluble interleukin-2 receptor (P=0.021), and soluble CD8 (P<0.039), than healthy controls; conversely, interferon-γ levels were significantly lower (P=0.023). Significant correlations were observed between β2-microglobulin concentration and Knodell's index (r=0.638,P=0.00045), the score of piecemeal necrosis (r=0.572,P=0.0023), and the degree of fibrosis (r=0.527,P=0.0056). Interleukin-2 levels correlated significantly with Knodell's index (r=0.412,P=0.037), and the degree of lobular cytolysis (r=0.389,P=0.048). According to therapeutic outcome, pretreatment levels of soluble CD8 were only significantly elevated (P=0.042) in patients with a sustained biochemical response. On interferon-α treatment, the levels of β2-microglobulin, neopterin, and soluble interleukin-2 receptor increased significantly (P<0.05), irrespective of therapy outcome. In summary, HCV patients have an altered immune reactivity that might play a role in the pathogenesis of chronic hepatitis C, and might influence the therapeutic outcome to interferon-γ.
      datePublished:
      dateModified:
      pageStart:2485
      pageEnd:2496
      sameAs:https://doi.org/10.1007/BF02087671
      keywords:
         chronic hepatitis C
         pathogenesis
         soluble immune factors
         interferon-α therapy
         Gastroenterology
         Hepatology
         Oncology
         Transplant Surgery
         Biochemistry
         general
      image:
      isPartOf:
         name:Digestive Diseases and Sciences
         issn:
            1573-2568
            0163-2116
         volumeNumber:39
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers-Plenum Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Juan Antonio Quiroga
            affiliation:
                  name:Hepatology Unit, Fundación Jiménez Díaz
                  address:
                     name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Julio Martin
            affiliation:
                  name:Hepatology Unit, Fundación Jiménez Díaz
                  address:
                     name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Margarita Pardo
            affiliation:
                  name:Hepatology Unit, Fundación Jiménez Díaz
                  address:
                     name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Vicente Carreño
            affiliation:
                  name:Hepatology Unit, Fundación Jiménez Díaz
                  address:
                     name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Digestive Diseases and Sciences
      issn:
         1573-2568
         0163-2116
      volumeNumber:39
Organization:
      name:Kluwer Academic Publishers-Plenum Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Hepatology Unit, Fundación Jiménez Díaz
      address:
         name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
         type:PostalAddress
      name:Hepatology Unit, Fundación Jiménez Díaz
      address:
         name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
         type:PostalAddress
      name:Hepatology Unit, Fundación Jiménez Díaz
      address:
         name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
         type:PostalAddress
      name:Hepatology Unit, Fundación Jiménez Díaz
      address:
         name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Juan Antonio Quiroga
      affiliation:
            name:Hepatology Unit, Fundación Jiménez Díaz
            address:
               name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:Julio Martin
      affiliation:
            name:Hepatology Unit, Fundación Jiménez Díaz
            address:
               name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:Margarita Pardo
      affiliation:
            name:Hepatology Unit, Fundación Jiménez Díaz
            address:
               name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:Vicente Carreño
      affiliation:
            name:Hepatology Unit, Fundación Jiménez Díaz
            address:
               name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
      name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
      name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
      name:Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(104)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

5.14s.